Home > Resources > Blogs
Why you don’t need a GMP-compound to start your first-in-human study
Fast clinical translation of your therapeutic compound: A stepwise approach
What quality grade labeled compounds do you need in your trials?
What is the optimal label to trace your compound?
How to design your first-in-human study: patient and tracer selection
Types of nuclear medicine imaging techniques
Four reasons to conduct your clinical trial in The Netherlands
Three Nuclear Imaging Strategies for Anti-inflammatory Drug Development
How to Use a Multimodal Imaging Approach in Clinical Trials
Gerard: ‘We both knew that what we were about to do could change the world’
The latest developments in fluorescence imaging
Radiopharmaceuticals are on the rise as drug developers realize enormous potential
How to determine clinical endpoints for fluorescence-guided surgery
How does cardiovascular imaging work?
How to generate in-human data on antibodies with microdosing
Hitting the R&D sweet spot with fast in-human studies
5 must read articles that changed the molecular imaging space
What are clinical molecular imaging studies?
The use of nuclear and optical molecular imaging in drug development
How to use in-human data as an investment strategy
How to transform your compound into in-human data in five steps
How to achieve a broad implementation of molecular imaging in drug development
How molecular imaging helps predict immunotherapy response